Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt de Vlam

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
The Journal of Rheumatology|February 12, 2010
Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008Christopher T Ritchlin, Abrar A Qureshi, Kurt de Vlam, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Vaccines|October 26, 2024
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study)Jeroen Geldof, Marie Truyens, João Sabino, et al.
Frontiers in Immunology|March 20, 2023
SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID studyJeroen Geldof, Marie Truyens, João Sabino, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Rheumatology and Therapy|December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X TrialAtul Deodhar, Philip Mease, Proton Rahman, et al.
Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
Osteoarthritis and Cartilage|June 24, 2025
Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trialYves Henrotin, Frédéric de Schrijver, Kurt De Vlam, et al.
JAMA|July 24, 2019
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical TrialMark C Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, et al.
The Journal of Rheumatology|July 15, 2024
Advances in Psoriatic Disease Research: Insights From GRAPPA Pilot Research AwardeesAshley Elliott, Tejpal Gill, Jaehwan Kim, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
The Journal of Rheumatology|February 12, 2010
Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008Christopher T Ritchlin, Abrar A Qureshi, Kurt de Vlam, et al.
Dermatology and Therapy|May 30, 2024
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis SeverityApril W Armstrong, Tarannum Jaleel, Joseph F Merola, et al.
Vaccines|October 26, 2024
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study)Jeroen Geldof, Marie Truyens, João Sabino, et al.
Frontiers in Immunology|March 20, 2023
SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID studyJeroen Geldof, Marie Truyens, João Sabino, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Rheumatology and Therapy|December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X TrialAtul Deodhar, Philip Mease, Proton Rahman, et al.
Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
Osteoarthritis and Cartilage|June 24, 2025
Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trialYves Henrotin, Frédéric de Schrijver, Kurt De Vlam, et al.
JAMA|July 24, 2019
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical TrialMark C Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, et al.
The Journal of Rheumatology|July 15, 2024
Advances in Psoriatic Disease Research: Insights From GRAPPA Pilot Research AwardeesAshley Elliott, Tejpal Gill, Jaehwan Kim, et al.
Pageof 14